

R₂ is selected from the group hydrogen, hydroxyl, C₁ – C₃ alkoxy, trifluoromethyl, nitro, cyano, halo, and

X is selected from the group [¹⁸F]-, [¹²³I]-, [¹²⁵I]-, and [¹³¹I]-.

35. (New): The compound as in claim 34 wherein the compound has a determinably high affinity to the TRP-M8 receptor characterized by a K_d of about 1 x 10⁻⁵ or less.

36. (New): The compound as in claim 34 wherein R' is ((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexyl)-.

REMARKS

In the Restriction Requirement the examiner has viewed the previously presented claims 1-25 as being 16 groups (I – XVI) for purposes of restriction. The examiner presents reasons why he/she believes the invention of each group is distinct from those of the others. However, applicant believes that 35 USC 121 requires a showing of both independence and distinctness before requiring restriction, and applicant therefore traverses this requirement.

Nevertheless, the examiner has required an election of a group, and **applicant therefore elects the group** designated as Group II pertaining to originally presented claims 1-8 and 11-16, where the alkyl moiety is a cyclohexane moiety. Because of the complexity of the restriction requirement, applicant herewith presents eleven new claims, all of which are directed to a specified compound wherein the alkyl moiety thereof includes a cyclohexane radical. Further, because the examiner has also required restriction between product and process claims in the originally filed claims 1 – 25, applicant has only

presented product claims in his new claims. However, applicant notes that when a product claim is subsequently found allowable, then process claims that depend from or otherwise include limitations of the patentable product will be entered as a matter of right if timely presented.

The examiner has further required election of a single patentable species.

Applicant elects the species wherein the alkyl moiety of the radioligand includes ((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexyl)-. This species is the subject of new claim 31 and new claim 35 (with two particularly preferred embodiments claimed in new claims 32 and 33).

Finally, Applicant submits an information disclosure statement together with copies of the cited references. Accordingly, this application is believed ready for substantive search and examination.

Respectfully submitted,

Wei.10



Edward T. Wei, Applicant
Cragmont Pharmaceuticals, LLC
480 Grizzly Peak Blvd., Berkeley, CA 94708
510/524-0414